What are biologic treatments? 

Biologic treatments represent a sophisticated category of medications derived from living cells that are designed to target specific components of the immune system. Unlike traditional chemically synthesised drugs, these therapies are engineered to intercept the biological signals that drive chronic inflammation and autoimmune responses. This guide explains the function of biologics within the UK healthcare system and how they are used to manage long-term conditions when standard therapies have not provided sufficient relief. 

What We’ll Discuss in This Article 

• The biological definition of biologic medicines and their origins 

• How biologic treatments target specific proteins in the immune system 

• The difference between conventional DMARDs and biologic therapies 

• The administration methods for biologics, including injections and infusions 

• The criteria for starting biologic treatment under UK guidelines 

• Important safety considerations and monitoring for patients 

Biologic treatments are medicines made from proteins and other substances produced by living cells that work by blocking specific chemicals in the immune system that cause inflammation and tissue damage. These therapies are often referred to as “biological DMARDs” because they modify the course of a disease rather than just treating the symptoms. According to the NHS, biological treatments are a newer type of medicine that are usually taken in combination with conventional DMARDs when those medicines have not worked well enough on their own. 

How Biologic Treatments Work 

The primary function of a biologic is to act like a precision-guided tool that identifies and neutralises specific “messenger” proteins in the body that trigger inflammation. In many autoimmune conditions, the immune system overproduces these proteins, leading to persistent swelling and damage in the joints or other organs. By blocking these specific pathways, biologics can effectively calm the immune response and prevent the progression of the disease. 

Common targets for biologic treatments include Tumour Necrosis Factor (TNF), interleukin-1, and interleukin-6. By focusing on these specific targets, biologics can often achieve results in patients who have not responded to broader, more traditional immune-suppressing medications. This targeted approach is intended to provide a more refined level of disease control, aiming for remission or significantly reduced disease activity. 

Differences Between Conventional and Biologic DMARDs 

It is important to understand that while both categories of medicine aim to control inflammation, they do so through very different biological mechanisms. Conventional synthetic DMARDs have a broad effect on the immune system, whereas biologics are highly specific. 

Feature	Conventional DMARDs (e.g. Methotrexate)	Biologic Treatments (e.g. TNF blockers)
Origin	Chemically synthesised in a laboratory	Produced from living cells or organisms
Mechanism	Broadly suppresses immune activity	Targets specific proteins or cells
Administration	Usually taken as tablets or weekly injections	Usually given via injection or intravenous infusion
Onset of Action	Can take 6 to 12 weeks to show effect	Often works more quickly, sometimes within 2 to 4 weeks
Monitoring	Frequent blood tests for liver and kidney health	Focus on infection risk and specific immune markers

Administration and Delivery Methods 

Because biologic treatments are large, complex proteins, they cannot be taken as tablets because the digestive system would break them down before they could reach the bloodstream. Therefore, they must be administered directly into the body. The NHS explains that biological treatments are usually given by an injection under the skin or through a drip into a vein in your arm. 

Patients are often taught how to perform these injections themselves at home using pre-filled pens or syringes, similar to how insulin is administered for diabetes. If the medicine is given via an infusion (a drip), the patient will usually attend a day clinic at a hospital where specialist nurses monitor the process. The frequency of these treatments varies widely depending on the specific drug, ranging from once a week to once every few months. 

Eligibility and UK Clinical Guidelines 

In the UK, the use of biologic treatments is strictly regulated by NICE guidelines to ensure they are used appropriately and cost-effectively. Generally, biologics are only considered after a patient has tried at least two conventional DMARDs without achieving sufficient disease control. A specialist rheumatologist must assess the severity of the condition using standardised scoring systems to determine if a patient meets the threshold for starting a biologic. 

Before starting treatment, patients must undergo screening for certain infections, such as tuberculosis (TB) and hepatitis. This is because biologics dampen specific parts of the immune system, which could allow a dormant infection to become active again. Once a patient starts a biologic, they will have regular reviews with their specialist team to ensure the medicine is working and that they are not experiencing significant side effects. 

Conclusion 

Biologic treatments are advanced therapies that target specific parts of the immune system to stop the inflammatory processes associated with autoimmune diseases. They are typically used when traditional medicines have not been effective and require careful administration via injection or infusion. While they offer a high level of disease control, they require ongoing specialist monitoring to ensure patient safety and effectiveness. If you experience severe, sudden, or worsening symptoms, call 999 immediately. 

Authority Snapshot (E-E-A-T Block) 

This guide provides evidence-based information on biologic treatments, following the established clinical standards of the NHS and NICE. The content is authored by the Medical Content Team and reviewed by Dr. Rebecca Fernandez, a UK-trained physician with extensive experience in internal medicine, cardiology, and emergency care. We aim to provide clear, factual, and safe information to help the public understand complex medical therapies within the UK healthcare framework.